Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Jun

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Metastatic Colorectal Cancer GUCY2C-Targeted CAR T-Cell Therapy

Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer

Machine Learning Model May Improve Accuracy of Liquid Biopsy Results